Key Takeaways:
The European Commission accused Sanofi of running a misleading campaign to boost sales of its Efluelda flu shot at the expense of rival Fluad.
The European Commission opened an antitrust investigation Friday into whether Sanofi SA breached EU competition rules by disparaging a rival flu vaccine in France and Germany, two markets where the French drugmaker holds a dominant position.
"The Commission is concerned that Sanofi pursued a misleading communication campaign to promote its Efluelda vaccine while disparaging CSL Seqirus' Fluad," the EU authority said in a statement Friday.
The probe follows unannounced raids on Sanofi's offices in September 2025. Sanofi said at the time it was confident it had complied with all relevant rules and would cooperate fully. The company reiterated that stance Friday, declining further comment on the investigation's specifics.
If found in breach of EU competition rules, Sanofi faces fines of as much as 10 percent of its annual global revenue — a penalty that, based on the company's 2025 sales of about 45 billion euros, could reach into the billions. The case also threatens to reshape how pharmaceutical companies market vaccines in Europe's two largest economies.
The probe centers on Sanofi's marketing of Efluelda, a high-dose influenza vaccine targeting adults aged 65 and older, and its alleged disparagement of Fluad, an adjuvanted flu shot from CSL Seqirus. Both products compete in the same segment of the seasonal influenza market, which generates billions of euros in annual sales across the European Union. Efluelda, launched in Europe in 2020, has been a key growth driver for Sanofi's vaccines division, which reported about 7.4 billion euros in revenue in 2025.
Sanofi's dominant position in France and Germany — two of the EU's largest pharmaceutical markets — gives the case added significance under European antitrust law. The Commission specifically cited the company's market power in those countries as a factor in its decision to open formal proceedings. Together, France and Germany account for more than 30 percent of the EU's pharmaceutical market by revenue, according to industry estimates.
A Pattern of Regulatory Scrutiny
The investigation adds to a growing list of EU antitrust actions targeting major pharmaceutical companies. European regulators have increasingly focused on marketing practices that may distort competition, particularly in markets where a single company holds significant pricing power. The September 2025 raids on Sanofi's premises signaled the Commission's interest months before Friday's formal announcement.
CSL Seqirus, the Australian biotech company that manufactures Fluad, has not publicly commented on the investigation. Its shares traded lower Friday on the Australian Securities Exchange following the news. Sanofi shares also declined in early Paris trading as investors weighed the potential financial and reputational consequences of the probe.
The Commission has not set a deadline for concluding the investigation. EU antitrust cases typically take two to three years to resolve, though preliminary findings may emerge sooner. Sanofi can present its defense and propose remedies to address the Commission's concerns during the proceedings. The outcome could set a precedent for how vaccine makers market competing products in the region.
This article is for informational purposes only and does not constitute investment advice.
